RT Journal Article
SR Electronic
T1 Emergence and spread of the potential variant of interest (VOI) B.1.1.519 predominantly present in Mexico
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.18.21255620
DO 10.1101/2021.05.18.21255620
A1 Rodríguez-Maldonado, Abril Paulina
A1 Vázquez-Pérez, Joel Armando
A1 Cedro-Tanda, Alberto
A1 Taboada, Blanca
A1 Boukadida, Celia
A1 Wong-Arámbula, Claudia
A1 Nuñez-García, Tatiana Ernestina
A1 Cruz-Ortiz, Natividad
A1 Barrera-Badillo, Gisela
A1 Hernández-Rivas, Lucía
A1 López-Martínez, Irma
A1 Mendoza-Vargas, Alfredo
A1 Reyes-Grajeda, Juan Pablo
A1 Alcaraz, Nicolas
A1 Peñaloza-Figueroa, Fernando
A1 Gonzalez-Barrera, Dulibeth
A1 Rangel-DeLeon, Daniel
A1 Herrera-Montalvo, Luis Alonso
A1 Mejía-Nepomuceno, Fidencio
A1 Hernández-Terán, Alejandra
A1 Mújica-Sánchez, Mario
A1 Becerril-Vargas, Eduardo
A1 Martínez-Orozco, José Arturo
A1 Pérez-Padilla, Rogelio
A1 Salas-Hernández, Jorge
A1 Sanchez-Flores, Alejandro
A1 Isa, Pavel
A1 Matías-Florentino, Margarita
A1 Ávila-Ríos, Santiago
A1 Muñoz-Medina, José Esteban
A1 Grajales-Muñiz, Concepción
A1 Salas-Lais, Angel Gustavo
A1 Coy-Arechavaleta, Andrea Santos
A1 Hidalgo-Miranda, Alfredo
A1 Arias, Carlos F.
A1 Ramírez-González, José Ernesto
YR 2021
UL http://medrxiv.org/content/early/2021/05/20/2021.05.18.21255620.abstract
AB SARS-CoV-2 variants have emerged in late 2020 and there are at least three variants of concern (B.1.1.7, B.1.351, P1) reported by WHO. These variants have several substitutions in the Spike protein that affect receptor binding; they present increased transmissibility and may be associated with reduced vaccine effectiveness. In the present work, we are reporting the identification of a potential variant of interest harboring the mutations T478K, P681H, and T732A in the Spike protein, within the newly named lineage B.1.1.519, which rapidly outcompeted the preexisting variants in Mexico and has been the dominant virus in the country during the first trimester of 2021.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partially supported by grants Epidemiologia Genomica de los Virus SARS-CoV-2 Circulantes en Mexico and Caracterizacion de la diversidad viral y bacteriana" from the National Council for Science and Technology (CONACyT) of Mexico to C.F.A. and J.A.V.P. respectively and also grants 057, 047 and 072 from the Ministry of Education, Science, Technology and Innovation (SECTEI) of Mexico City to C.F.A., L.H.M. y A.H.M. respectivelyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Residual RNA positive samples were recovered and sequenced from routine SARS CoV-2 diagnostic and were processed following Standardized Guideline for Epidemiological and Laboratory surveillance of Viral Respiratory Disease (https://www.gob.mx/cms/uploads/attachment/file/610162/Lineamiento_VE_y_Lab_Enf_Viral_Ene-2021_290121.pdf) emitted and approved by the CONAVE (National Counsel of Epidemiology Surveillance) of the Secretariat of Health, Government of Mexico. This work was also approved for the Ethics Committee on Research of the National Institute of Genomic Medicne with the registration number of the National Bioethics Commission CONBIOETICA-09-CEI-008-20180615 under the opinion number CEI 2020/20. All data obtained in this work are directly related to disease control and were openly available at the GISAID website to the public before the initiation of the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available on GISAID website https://www.gisaid.org/